Cargando…

Ramucirumab: preclinical research and clinical development

Ramucirumab (IMC-1121B, LY3009806), a fully humanized monoclonal antibody directed against the extracellular domain of vascular endothelial growth factor receptor 2 (VEGFR-2), is a new therapeutic option that selectively inhibits the human VEGFR-2 with a much greater affinity than its natural ligand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aprile, Giuseppe, Rijavec, Erika, Fontanella, Caterina, Rihawi, Karim, Grossi, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4218907/ https://www.ncbi.nlm.nih.gov/pubmed/25378934 http://dx.doi.org/10.2147/OTT.S61132

Ejemplares similares

Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials
por: Aprile, Giuseppe, et al.
Publicado: (2015)

Clinical utility of ramucirumab in advanced gastric cancer
por: Chan, Matthew MK, et al.
Publicado: (2015)

Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review
por: Indini, Alice, et al.
Publicado: (2021)

Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
por: Indini, Alice, et al.
Publicado: (2021)

Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity
por: Cobo, Manuel, et al.
Publicado: (2017)

Clinical utility of ramucirumab in non-small-cell lung cancer
por: Uprety, Dipesh
Publicado: (2019)

Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy
por: Choucair, Khalil, et al.
Publicado: (2021)

Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib
por: Rijavec, Erika, et al.
Publicado: (2022)

Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
por: Indini, Alice, et al.
Publicado: (2021)

Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab
por: Hata, Akito, et al.
Publicado: (2018)

Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab
por: Ruzzo, Annamaria, et al.
Publicado: (2020)

Developing a risk assessment score for patients with cancer during the coronavirus disease 2019 pandemic
por: Indini, Alice, et al.
Publicado: (2020)

Novel treatment strategies for early-stage lung cancer: the oncologist’s perspective
por: Indini, Alice, et al.
Publicado: (2020)

Letter of response to comments on: Developing a risk assessment score for patients with cancer during COVID-19 pandemic: A war on two fronts
por: Indini, Alice, et al.
Publicado: (2020)

TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy
por: Graziano, Francesco, et al.
Publicado: (2020)

Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges
por: Rijavec, Erika, et al.
Publicado: (2019)

Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma
por: Davidson, Michael, et al.
Publicado: (2016)

Ramucirumab: A New Therapy for Advanced Gastric Cancer
por: Oholendt, Andrea Landgraf, et al.
Publicado: (2015)

Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers
por: ElHalawani, Hesham, et al.
Publicado: (2015)

Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis
por: Indini, Alice, et al.
Publicado: (2020)

Health Information Technology in Oncology Practice: A Literature Review
por: Fasola, G, et al.
Publicado: (2014)

Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancer
por: Cooper, Maryann R, et al.
Publicado: (2016)

The Impact of Ramucirumab Treatment on Survival and Quality of Life in Patients with Gastric Cancer
por: Mehta, Rutika, et al.
Publicado: (2020)

Molecular mechanisms of synergistic action of Ramucirumab and Paclitaxel in Gastric Cancers cell lines
por: Refolo, Maria Grazia, et al.
Publicado: (2020)

Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein
por: Gilabert, Marine, et al.
Publicado: (2018)

How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?
por: Chen, Ming-Huang, et al.
Publicado: (2021)

Schistosome Vaccine Adjuvants in Preclinical and Clinical Research
por: Stephenson, Rachel, et al.
Publicado: (2014)

Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence
por: De Luca, Emmanuele, et al.
Publicado: (2020)

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
por: Harding, James J., et al.
Publicado: (2021)

Capecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients’ heart?
por: Fontanella, Caterina, et al.
Publicado: (2014)

Immuno-oncology trends: preclinical models, biomarkers, and clinical development
por: Franklin, Maryland Rosenfeld, et al.
Publicado: (2022)

Population pharmacokinetic meta‐analysis of ramucirumab in cancer patients
por: O'Brien, Lisa, et al.
Publicado: (2017)

Gastric perforation related to concurrent use of nintedanib and ramucirumab
por: Takahashi, Saeko, et al.
Publicado: (2018)

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
por: Gil-Delgado, Maria Angeles, et al.
Publicado: (2018)

Delayed Healing of Tooth Extraction Sockets with Ramucirumab Use
por: Iijima, Yosuke, et al.
Publicado: (2020)

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab
por: Reig, Maria, et al.
Publicado: (2020)

Ramucirumab-Induced Hepatocellular Carcinoma Rupture and Gastrointestinal Perforation
por: Haider, Asim, et al.
Publicado: (2021)

Ramucirumab in the second-line treatment of metastatic colorectal cancer: a narrative review of literature from clinical trials
por: Chen, Chou-Pin, et al.
Publicado: (2020)

HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives
por: Fanotto, Valentina, et al.
Publicado: (2016)

Preclinical and Clinical Applications of Metabolomics and Proteomics in Glioblastoma Research
por: Ahmed, Munazza, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u750o7qj8j8d4l5quke0d0316a